Market Overview

Notable Insider Buys: AbbVie, Bristol-Myers And More

Notable Insider Buys: AbbVie, Bristol-Myers And More
  • Insider buying can be an encouraging signal for potential investors.
  • Insiders were buying shares last week in the wake of earnings reports.
  • Two big drugmakers saw sizable insider purchases in the past week.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly with markets near all-time highs.

Below is a look at a few notable insider purchases reported in the past week, but note that there were also some smaller insider purchases at Mastercard Inc (NYSE: MA) and Tesla Inc (NASDAQ: TSLA).

Trinity Industries

A director at Trinity Industries Inc (NYSE: TRN) indirectly purchased almost 659,000 shares of this Dallas-based company to end July. At prices ranging from $18.81 to $19.84 per share, that cost the director more than $12.68 million. Note also that an executive sold more than 2,000 shares back in May.

The transportation products and services provider posted its quarterly results before these transactions. The stock ended the past week at $19.50 per share, which is still within the director's purchase range. While the consensus target price was last seen at $27.33, the analysts do not recommend buying shares at this time.

See Also: Jeff Bezos Sells 900K Amazon Shares, Stake Drops From 16% To 12%


Last week, an AbbVie Inc (NYSE: ABBV) director and an executive acquired 95,000 shares altogether of this pharmaceutical company. At prices ranging from $65.30 to $67.32 per share, those transactions totaled more than $6.30 million. Note also that more than 49,000 shares were purchased by insiders in the previous week.

AbbVie recently posted better than expected second-quarter results and raised its full-year guidance. The shares have pulled back since, more than the broader markets, and ended the past week trading at $65.35. The analysts' consensus target is $86.00, though the stock has traded as high as $100.23 in the past 52 weeks.


Bristol-Myers Squibb Co. (NYSE: BMY) also saw a director step up to the buy window. At an average price of $44.72 apiece, the 11,000 shares reportedly acquired last week totaled nearly $492,000. Note that another director bought 5,000 shares back in May, but at a price of more than $47 apiece.

This pharma giant also posted better than expected earnings and raised its fiscal year guidance. Shares ended the past week at $45.99, above the above-mentioned purchase price range. Note that the shares have traded as high as $63.69 in the past 52 weeks, though the analysts' consensus price target is just $54.50.

Posted-In: AbbVie bristol-myers bristol-myers squibb mastercard Tesla trinity industriesNews Insider Trades Best of Benzinga


Related Articles (BMY + ABBV)

View Comments and Join the Discussion!

Charts: CBD Search Interest Is More Popular Than Beyonce, Kim Kardashian And Veganism

Clever Leaves Completes First Hemp-Based CBD Products Commercial Export From Colombia To UK